OTCM
REVXF
Market cap358mUSD
Jun 30, Last price
34.80
Name
Revenio Group Oyj
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Revenio Group Oyj operates as a healthcare technology company, specializing in the development, production, and global distribution of advanced ophthalmic diagnostic instruments and medical devices. These innovations are engineered to aid in the identification of various eye conditions, including glaucoma, macular degeneration, diabetic retinopathy, and cataracts, serving clientele in Finland, throughout Europe, and worldwide. Its extensive product portfolio includes the iCare IC100 and IC200 tonometers, along with the iCare HOME device for personal eye pressure monitoring. Furthermore, the company provides sophisticated imaging technologies such as the iCare EIDON AF for confocal retinal imaging, DRSplus for screening diabetic retinopathy, the iCare MAIA microperimeter for precise visual field measurements, and iCare COMPASS, which facilitates fundus perimetry using true-color retinal images. Beyond hardware, Revenio also offers Oculo, a comprehensive eye care software platform that seamlessly integrates clinical communication, telehealth functionalities, remote patient monitoring, and robust data analytics. Established in 2001, Revenio Group Oyj is based in Vantaa, Finland.
Key people
Jouni Toijala
President, Chief Executive Officer, Member of the Management Board · since 2022
Ari Isomaeki
Vice President - Operations, Member of the Management Board · since 2021
Kate Taylor
Vice President - Strategy and Business Development, Member of the Management Board · since 2023
John Floyd
Vice President - Sales, Member of the Management Board · since 2023
Erkki Tala
Vice President - Products, Brand and Marketing, Member of the Management Board · since 2024
Hanna Vuornos
Vice President of People and Culture, Member of the Management Board · since 2021
Heli Huopaniemi
Vice President - Quality, Member of the Management Board · since 2021
Robin Pulkkinen
Chief Financial Officer, Member of the Management Team · since 2015
Marco Rizzardo
Vice President - Research & Development, Member of the Management Board · since 2024
Independent Director · since 2025
Anat Loewenstein
Independent Director · since 2025
Arne Nielsen
Independent Chairman of the Board · since 2022
Bill Oestman
Independent Director · since 2020
Riad Sherif
Independent Director · since 2022
Independent Director · since 2016
Pekka Tammela
Independent Director · since 2018
Headquarters & legal address
Härkähaankuja 7
01730 VANTAA
VANTAA FI-01730
FI
01730 VANTAA
VANTAA FI-01730
FI
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||